STLT Spotlight Innovation Inc.
Mod:
Ecomike
Last Post:
07/24/18
Followers:
1
Posts Today:
0
Views Today:
1
Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies which have unique intellectual property (IP) in the medical sector. The Company utilizes relationships with the nation’s leading academic and institutional IP developers to locate promising IP technologies with potential for market share capture. With their support, development, resources and strategic planning expertise, Spotlight Innovation believes they can develop IP that will have a positive effect on healthcare. They intend to partner with proven sector leaders on commercialization once technologies are fully developed.
http://www.spotlightinnovation.com/download-whitepaper/
Website: http://www.spotlightinnovation.com
LinkedIn Company Page: http://www.linkedin.com/company/spotlight-innovation
YouTube/Google+ Company: http://www.youtube.com/user/spotlightinnovation
Twitter: https://twitter.com/SpotlightInno
Facebook: https://www.facebook.com/SpotlightInnovation
SPOTLIGHT INNOVATION INC.
6750 Westown Pkwy, Suite 200-226
West Des Moines, IA 50266
Phone: 515-274-9087
Milestones:
2015
JANUARY 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office
JANUARY 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC
2014
OCTOBER 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals
SEPTEMBER 2014
Spotlight Innovation retains Jerry Cirino as Special Advisor
SEPTEMBER 2014
Spotlight Innovation retains Barwicki Investor Relations
AUGUST 2014
Spotlight Innovation publishes White Paper “Midwest Universities are Cultivating IP Commercialization Success”
JULY 2014
Spotlight Innovation receives $250,000 Line of Credit from Denver Savings Bank
JUNE 2014
Spotlight Innovation hires Dr. Hostelley as CFO
JUNE 2014
Spotlight Innovation closes equity placement of more than $41M: released to Company under certain specified conditions
JUNE 2014
Share exchange agreement finalized between Celtic Biotech Iowa and Celtic Biotech LTD, completing Celtic Biotech LTD acquisition
APRIL 2014
Spotlight Innovation receives $752,325 Line of Credit from Denver Savings Bank, secured by Jared DeVries
MARCH 2014
Celtic Biotech Iowa, Inc., becomes wholly-owned subsidiary of Spotlight Innovation Inc.
2013
DECEMBER 2013
AEXP/Spotlight Innovation merger completed
March 10, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa licenses promising therapy for Chronic Kidney Disease
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD).
Read more…
January 15, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Read more…
January 6, 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC
Spotlight Innovation Inc. (OTCQB:STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Read more…
December 16, 2014
Spotlight Innovation announces change of Transfer Agent
Spotlight Innovation Inc. (OTCQB:STLT) announces today that effective December 16, 2014, all communications related to shareholder transactions should be directed to VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
Read more…
December 4, 2014
Celtic Biotech Iowa requests reactivation and transfer of National Drug Code registration
Spotlight Innovation Inc. (OTCQB:STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product.
Read more…
October 14, 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals
Spotlight Innovation Inc. (OTCQB:STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex™ vaccine platform technology, which is designed to use the body’s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Read more…
October 1, 2014
Spotlight Innovation Retains Jerry Cirino as Special Advisor
Spotlight Innovation Inc. (OTCQB: STLT) has hired Jerry Cirino as a Special Advisor to provide business development expertise and to advise the Company on strategic opportunities and transactions.
Read more…
September 24, 2014
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program
Spotlight Innovation, Inc. (OTCQB: STLT) announced that it has retained Barwicki Investor Relations, a New York-based investor relations firm, to expand the Company’s strategic investor relations program. Barwicki Investor Relations is providing financial community and media relations, and editorial, consulting and advisory services.
Read more…
August 27, 2014
Spotlight Innovation white paper focuses on evolution of efforts to transform University research into profitable business ventures
Spotlight Innovation, Inc. (OTCQB:STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP).
Read more…
August 5, 2014
Spotlight Innovation signs second Letter of Credit with Denver Savings Bank
Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Read more…
July 02, 2014
Spotlight Innovation, Inc., announces closing of financing
Spotlight Innovation, Inc., (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors, through its equity advisor Catwalk Capital, LLC.
Read more…
June 26, 2014
Spotlight Innovation names Dr. David Hostelley Chief Financial Officer
Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company.
Read more…
June 17, 2014
Spotlight Innovation building relationships with Midwest businesses and people
Cristopher Grunewald, President and CEO of Spotlight Innovation said, “The Midwest is a hotbed of talent and innovation, and it has always been a pillar of our business plan to build relationships with people and institutions in the Midwest. We are pleased that we are making good on this commitment.”
Read more…
June 10, 2014
Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., completes merger with Celtic Biotech Ltd.
Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 4, 2014, Celtic Biotech Iowa, Inc. (a subsidiary of Spotlight Innovation, Inc.) has completed a share exchange agreement with biopharmaceutical company Celtic Biotech Ltd.
Read more…
December, 16, 2013
Spotlight Innovation’s name change, symbol change and reverse split approved by FINRA
Spotlight Innovation, Inc. (“the Company”) (OTCQB:STLT) is pleased to announce that effective December 17, 2013 the Financial Industry Regulatory Authority (“FINRA”) has approved the name change of the company from American Exploration Corp. to Spotlight Innovation, Inc., change of stock symbol to “STLT”, and a 1-500 reverse split of our common stock.
Read more…
December 12, 2013
Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
Spotlight Innovation, Inc. (formerly American Exploration Corporation, AEXP:OTCQB), announced today the completion of a merger with Spotlight Innovation, LLC.
Read more…
Spotlight Innovation is committed to developing quality-of-life-enhancing biotechnologies that have the potential to positively impact the health, well-being and longevity of an enormous number of lives. We are building a portfolio of healthcare/life sciences subsidiary companies, each having the potential to further our commitment.
Celtic Biotech Iowa Inc.
Celtic Biotech, Inc.
Celtic Biotech Iowa Inc., is developing novel therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.
Celtic Biotech Iowa Inc. is a subsidiary of Spotlight Innovation Inc.
Read the press release here.
Additional information about Celtic Biotech here.
Celtic Biotech Iowa Inc.
Management
Cristopher Grunewald, CEO
Mr. Grunewald is a financial executive and entrepreneur with background in the healthcare and biotechnology sectors, private equity and investment banking. He has been involved in all stages of the commercialization of healthcare IP developed by premiere research and development institutions.
Dr. David Hostelley, CFO
Dr. Hostelley has twenty years as a consultant in the health field, and has served as CEO, CFO and board member of several publicly traded companies. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio.
Jeffrey Stein, Esq., Securities Counsel
Mr. Stein serves as securities counsel for Spotlight Innovation. He has over fifteen years of experience providing high quality, personalized attention to public companies, including more than thirty reverse mergers, IPOs and APOs.
Rene Erickson, Corporate Communications
Mr. Erickson has three decades of corporate communications experience across diverse industries including healthcare, information technology, aviation and academia.
Mike Reysack, Investor Relations
Mr. Reysack leads Investor Relations for Spotlight Innovation. He has extensive experience cultivating and managing relationships with financial stakeholders, including fifteen years as an Investor Relations consultant and business strategist for venture and early stage companies, providing effective communications between companies and the financial community.
Special Advisor
Jerry Cirino
Mr. Cirino is a healthcare technology executive with extensive background in medical devices, distribution and healthcare information in private equity and public environments. His experience includes management of complex growth and transition environments including M&A, integrations and global operations, and he is a proven consultant in transaction evaluation, due diligence and strategic planning.
Partner Firms
Auditor
GBH CPAs, PC, Houston, TX
Transfer Agent
VStock Transfer, LLC, Woodmere, NY
Law Firms
Davis Brown Law Firm, Des Moines, IA
JMS Law Group, New York, NY
Eilers Law Group, Miami, FL
Whitfield & Eddy, P.L.C., Des Moines, IA
http://www.spotlightinnovation.com/download-whitepaper/
Website: http://www.spotlightinnovation.com
LinkedIn Company Page: http://www.linkedin.com/company/spotlight-innovation
YouTube/Google+ Company: http://www.youtube.com/user/spotlightinnovation
Twitter: https://twitter.com/SpotlightInno
Facebook: https://www.facebook.com/SpotlightInnovation
SPOTLIGHT INNOVATION INC.
6750 Westown Pkwy, Suite 200-226
West Des Moines, IA 50266
Phone: 515-274-9087
Milestones:
2015
JANUARY 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office
JANUARY 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC
2014
OCTOBER 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals
SEPTEMBER 2014
Spotlight Innovation retains Jerry Cirino as Special Advisor
SEPTEMBER 2014
Spotlight Innovation retains Barwicki Investor Relations
AUGUST 2014
Spotlight Innovation publishes White Paper “Midwest Universities are Cultivating IP Commercialization Success”
JULY 2014
Spotlight Innovation receives $250,000 Line of Credit from Denver Savings Bank
JUNE 2014
Spotlight Innovation hires Dr. Hostelley as CFO
JUNE 2014
Spotlight Innovation closes equity placement of more than $41M: released to Company under certain specified conditions
JUNE 2014
Share exchange agreement finalized between Celtic Biotech Iowa and Celtic Biotech LTD, completing Celtic Biotech LTD acquisition
APRIL 2014
Spotlight Innovation receives $752,325 Line of Credit from Denver Savings Bank, secured by Jared DeVries
MARCH 2014
Celtic Biotech Iowa, Inc., becomes wholly-owned subsidiary of Spotlight Innovation Inc.
2013
DECEMBER 2013
AEXP/Spotlight Innovation merger completed
March 10, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa licenses promising therapy for Chronic Kidney Disease
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD).
Read more…
January 15, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Read more…
January 6, 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC
Spotlight Innovation Inc. (OTCQB:STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Read more…
December 16, 2014
Spotlight Innovation announces change of Transfer Agent
Spotlight Innovation Inc. (OTCQB:STLT) announces today that effective December 16, 2014, all communications related to shareholder transactions should be directed to VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
Read more…
December 4, 2014
Celtic Biotech Iowa requests reactivation and transfer of National Drug Code registration
Spotlight Innovation Inc. (OTCQB:STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product.
Read more…
October 14, 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals
Spotlight Innovation Inc. (OTCQB:STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex™ vaccine platform technology, which is designed to use the body’s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Read more…
October 1, 2014
Spotlight Innovation Retains Jerry Cirino as Special Advisor
Spotlight Innovation Inc. (OTCQB: STLT) has hired Jerry Cirino as a Special Advisor to provide business development expertise and to advise the Company on strategic opportunities and transactions.
Read more…
September 24, 2014
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program
Spotlight Innovation, Inc. (OTCQB: STLT) announced that it has retained Barwicki Investor Relations, a New York-based investor relations firm, to expand the Company’s strategic investor relations program. Barwicki Investor Relations is providing financial community and media relations, and editorial, consulting and advisory services.
Read more…
August 27, 2014
Spotlight Innovation white paper focuses on evolution of efforts to transform University research into profitable business ventures
Spotlight Innovation, Inc. (OTCQB:STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP).
Read more…
August 5, 2014
Spotlight Innovation signs second Letter of Credit with Denver Savings Bank
Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Read more…
July 02, 2014
Spotlight Innovation, Inc., announces closing of financing
Spotlight Innovation, Inc., (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors, through its equity advisor Catwalk Capital, LLC.
Read more…
June 26, 2014
Spotlight Innovation names Dr. David Hostelley Chief Financial Officer
Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company.
Read more…
June 17, 2014
Spotlight Innovation building relationships with Midwest businesses and people
Cristopher Grunewald, President and CEO of Spotlight Innovation said, “The Midwest is a hotbed of talent and innovation, and it has always been a pillar of our business plan to build relationships with people and institutions in the Midwest. We are pleased that we are making good on this commitment.”
Read more…
June 10, 2014
Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., completes merger with Celtic Biotech Ltd.
Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 4, 2014, Celtic Biotech Iowa, Inc. (a subsidiary of Spotlight Innovation, Inc.) has completed a share exchange agreement with biopharmaceutical company Celtic Biotech Ltd.
Read more…
December, 16, 2013
Spotlight Innovation’s name change, symbol change and reverse split approved by FINRA
Spotlight Innovation, Inc. (“the Company”) (OTCQB:STLT) is pleased to announce that effective December 17, 2013 the Financial Industry Regulatory Authority (“FINRA”) has approved the name change of the company from American Exploration Corp. to Spotlight Innovation, Inc., change of stock symbol to “STLT”, and a 1-500 reverse split of our common stock.
Read more…
December 12, 2013
Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
Spotlight Innovation, Inc. (formerly American Exploration Corporation, AEXP:OTCQB), announced today the completion of a merger with Spotlight Innovation, LLC.
Read more…
Spotlight Innovation is committed to developing quality-of-life-enhancing biotechnologies that have the potential to positively impact the health, well-being and longevity of an enormous number of lives. We are building a portfolio of healthcare/life sciences subsidiary companies, each having the potential to further our commitment.
Celtic Biotech Iowa Inc.
Celtic Biotech, Inc.
Celtic Biotech Iowa Inc., is developing novel therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.
Celtic Biotech Iowa Inc. is a subsidiary of Spotlight Innovation Inc.
Read the press release here.
Additional information about Celtic Biotech here.
Celtic Biotech Iowa Inc.
Management
Cristopher Grunewald, CEO
Mr. Grunewald is a financial executive and entrepreneur with background in the healthcare and biotechnology sectors, private equity and investment banking. He has been involved in all stages of the commercialization of healthcare IP developed by premiere research and development institutions.
Dr. David Hostelley, CFO
Dr. Hostelley has twenty years as a consultant in the health field, and has served as CEO, CFO and board member of several publicly traded companies. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio.
Jeffrey Stein, Esq., Securities Counsel
Mr. Stein serves as securities counsel for Spotlight Innovation. He has over fifteen years of experience providing high quality, personalized attention to public companies, including more than thirty reverse mergers, IPOs and APOs.
Rene Erickson, Corporate Communications
Mr. Erickson has three decades of corporate communications experience across diverse industries including healthcare, information technology, aviation and academia.
Mike Reysack, Investor Relations
Mr. Reysack leads Investor Relations for Spotlight Innovation. He has extensive experience cultivating and managing relationships with financial stakeholders, including fifteen years as an Investor Relations consultant and business strategist for venture and early stage companies, providing effective communications between companies and the financial community.
Special Advisor
Jerry Cirino
Mr. Cirino is a healthcare technology executive with extensive background in medical devices, distribution and healthcare information in private equity and public environments. His experience includes management of complex growth and transition environments including M&A, integrations and global operations, and he is a proven consultant in transaction evaluation, due diligence and strategic planning.
Partner Firms
Auditor
GBH CPAs, PC, Houston, TX
Transfer Agent
VStock Transfer, LLC, Woodmere, NY
Law Firms
Davis Brown Law Firm, Des Moines, IA
JMS Law Group, New York, NY
Eilers Law Group, Miami, FL
Whitfield & Eddy, P.L.C., Des Moines, IA
